L. Fiorino

Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small‐Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis

M. Lesperance, D. Fenton, D. Ksienski, 2019, Clinical lung cancer.

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab

A. T. Freeman, M. Lesperance, D. Fenton, 2020, Translational lung cancer research.

Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.

A. T. Freeman, M. Lesperance, D. Fenton, 2019, Lung cancer.

Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.

A. T. Freeman, M. Lesperance, D. Fenton, 2020, Journal of geriatric oncology.

Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.

A. T. Freeman, M. Lesperance, D. Fenton, 2019, Current oncology.

Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience

A. Tinker, Aalok Kumar, Helena M. O'Dwyer, 2018, International Journal of Gynecologic Cancer.